| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-08-03 | Burnett Patrick | officer | Sale | 955 | $26.12 | $25K |
| 2026-08-03 | Matsuda Masaru | officer | Sale | 1,230 | $26.12 | $32K |
| 2026-08-03 | Watanabe Todd | director, officer | Sale | 4,375 | $26.12 | $114K |
| 2026-06-05 | Heron Patrick J | director | Award | 5,778 | — | — |
| 2026-06-05 | Heron Patrick J | director | Award | 16,667 | $21.23 | $354K |
| 2026-06-05 | LIN SUE-JEAN | director | Award | 5,778 | — | — |
| 2026-06-05 | LIN SUE-JEAN | director | Award | 16,667 | $21.23 | $354K |
| 2026-06-05 | Welgus Howard G. | director | Award | 5,778 | — | — |
| 2026-06-05 | Welgus Howard G. | director | Award | 16,667 | $21.23 | $354K |
| Filed | Form | Filer | Stake | Shares | |
|---|---|---|---|---|---|
| 2026-08-07 | SCHEDULE 13G | STATE STREET CORP | — | — | view → |
| 2023-10-26 | SC | Frazier Life Sciences VIII, L.P. | — | — | view → |
| 2021-05-12 | SC | Frazier Life Sciences VIII, L.P. | — | — | view → |
| 2021-02-09 | SC | Frazier Life Sciences VIII, L.P. | — | — | view → |
| 2021-02-09 | SC | ORBIMED ADVISORS LLC | — | — | view → |
| 2021-02-08 | SC | Bain Capital Life Sciences Fund, L.P. | — | — | view → |
| 2020-10-07 | SC | ORBIMED ADVISORS LLC | — | — | view → |
| Filed | Form | Issuer | Stake | Shares | |
|---|---|---|---|---|---|
| 2026-09-10 | SCHEDULE 13D/A | Braveheart Bio, Inc. | 13.50% | 12,175,159 | view → |
| 2026-08-18 | SCHEDULE 13D | BlossomHill Therapeutics, Inc. | 8.90% | 2,714,279 | view → |
| 2026-08-18 | SCHEDULE 13D | Braveheart Bio, Inc. | 17.20% | 12,175,159 | view → |
| 2026-08-10 | SCHEDULE 13D/A | MBX Biosciences, Inc. | — | 3,074,853 | view → |
| 2026-08-05 | SCHEDULE 13D | Yarrow Bioscience, Inc. | 9.97% | 266,306 | view → |
| 2026-07-29 | SCHEDULE 13D | Scribe Therapeutics, Inc. | 7.20% | 1,348,825 | view → |
| 2026-07-20 | SCHEDULE 13D/A | Q32 Bio Inc. | — | 4,127,987 | view → |
| 2026-06-24 | SCHEDULE 13D/A | Enliven Therapeutics, Inc. ELVN | — | 6,774,507 | view → |
| 2026-06-17 | SCHEDULE 13D/A | Enliven Therapeutics, Inc. ELVN | 10.93% | 7,634,630 | view → |
| 2026-06-15 | SCHEDULE 13D/A | Shattuck Labs, Inc. STTK | — | 9,021,127 | view → |
| 2026-06-01 | SCHEDULE 13D/A | Q32 Bio Inc. QTTB | — | 4,127,987 | view → |
| 2026-04-10 | SCHEDULE 13D/A | Adicet Bio, Inc. ACET | 8.80% | 844,787 | view → |
| 2026-01-27 | SCHEDULE | Corvus Pharmaceuticals, Inc. CRVS | 10.30% | 8,609,091 | view → |
| 2025-10-10 | SCHEDULE | Adicet Bio, Inc. ACET | 9.60% | 14,772,598 | view → |
| 2025-09-30 | SCHEDULE | MBX Biosciences, Inc. MBX | 9.00% | 4,002,887 | view → |
| 2025-07-21 | SCHEDULE | Passage BIO, Inc. PASG | 7.82% | 243,878 | view → |
| 2025-05-14 | SCHEDULE | Corvus Pharmaceuticals, Inc. CRVS | 12.20% | 9,785,423 | view → |
| 2025-04-11 | SCHEDULE | Compass Therapeutics, Inc. CMPX | 11.00% | 15,219,994 | view → |
| 2025-01-29 | SCHEDULE | Traws Pharma, Inc. TRAW | 19.90% | 760,824 | view → |
| 2024-11-12 | SC | Third Harmonic Bio, Inc. | — | — | view → |
Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.
See pricing →